Recombinant escherichia coli for producing deoxyviolacein and application thereof
By knocking out and expressing recombinant E. coli with specific genes, efficient production of deoxypuromycin under the condition of no addition of tryptophan is achieved, solving the problem of high production costs in the prior art and achieving the potential for industrial application.
Patent Information
- Application Number
- CN202411047708.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to efficiently produce deoxypuromin, and due to the high cost of high concentration of L-tryptophan, it is difficult to meet the needs of industrial production, and there is no precedent for fermentation under the conditions of adding precursor tryptophan.
By knocking out the tryptophan gene, tryptophan operon transcription inhibitor and branched acid dehydrase gene in E. coli, and freely express vioA, vioB, vioC and vioE genes in Bacillus vioci while overexpressing endogenous properties The trpE, trpD, aroG and serA genes use specific vectors and promoters to control gene expression, and construct recombinant E. coli to achieve efficient biosynthesis of deoxypuromycin.
Without additional tryptophan, recombinant E. coli can efficiently produce deoxypuromycin, with a yield of 348mg/L, reducing production costs and having industrial application potential.
Smart Images

Figure BDA0004973962870000061 
Figure BDA0004973962870000071 
Figure BDA0004973962870000081
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological gene engineering and relates to recombinant Escherichia coli, in particular to a recombinant Escherichia coli producing deoxypurpurogenin and application thereof. Background Art
[0002] Deoxyviolacein is a secondary metabolite of purple microorganisms, which has antibacterial activity against Gram-positive bacteria such as Staphylococcus aureus, Bacillus giant, Bacillus subtilis and fungi. In 1959, DeMoss et al. discovered deoxyviolacein, a byproduct of the production process of violacein. Deoxyviolacein is a structural analog of violacein, the difference being that it lacks a hydroxyl group at the 5th position of the indole ring. The biosynthesis of deoxyviolacein involves four enzymatic reactions catalyzed by vioA, vioB, vioC and vioE. First, L-tryptophan oxidase (VioA) catalyzes the oxidative deamination reaction of L-tryptophan in the presence of flavin adenine dinucleotide (FAD) to produce indole-3-pyruvate (IPA); then, IPA is converted into IPA imine dimer (CAP) by polyketide synthase (VioB); finally, VioE converts CAP into protodeoxyviolaceum, which is oxidized into deoxyviolaceum by monooxygenase (VioC).
[0003] Since deoxypurpurogenin accounts for a small proportion of purpurogenin derivatives, it is difficult to separate and obtain sufficient amount to study its properties and functions. At present, its functions and potential applications need further research and development. With the development of synthetic microbiology and metabolic engineering, heterologous fermentation production of purpurogenin derivatives has become possible. Escherichia coli has a clear genetic background, can efficiently express foreign genes, has simple related technical operations, and has a short culture cycle. It is one of the most commonly used model chassis microorganisms for engineered production of chemicals.
[0004] L-tryptophan is the main precursor for the synthesis of deoxypurpurogenin. High concentrations of L-tryptophan will correspondingly produce high yields of deoxypurpurogenin, so it is crucial to maintain a high L-tryptophan flux. At present, in order to increase the yield, the precursor tryptophan is often added to the culture medium, but the cost of adding tryptophan (an essential amino acid) is high and cannot meet the needs of large-scale industrial production at this stage. Moreover, there is no precedent for fermenting deoxypurpurogenin without adding the precursor tryptophan. Summary of the invention
[0005] The purpose of the present invention is to provide a recombinant Escherichia coli that can efficiently produce deoxyviolacein from scratch, and achieve the purpose of biosynthesizing deoxyviolacein by optimizing the Escherichia coli strain, while reducing the amount of tryptophan used, thereby reducing production costs;
[0006] Another object of the present invention is to provide an application of the above-mentioned recombinant Escherichia coli.
[0007] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0008] A recombinant Escherichia coli producing deoxyviolacein is prepared by using Escherichia coli as a starting strain, knocking out one or more genes of a tryptophanase gene tnaA, a tryptophan operon transcription inhibitor gene trpR and a chorismate dehydratase gene pheA, and expressing vioA gene, vioB gene, vioC gene and vioE gene in violacein in a free manner;
[0009] The Gene ID of tnaA is 948221, the Gene ID of trpR is 948917, and the Gene ID of pheA is 947081.
[0010] As a limitation, the vioA gene, vioB gene, vioC gene and vioE gene are codon optimized;
[0011] The nucleotide sequence of the codon-optimized vioA gene is shown in SEQ ID NO.1, the nucleotide sequence of the codon-optimized vioB gene is shown in SEQ ID NO.2, the nucleotide sequence of the codon-optimized vioC gene is shown in SEQ ID NO.3, and the nucleotide sequence of the codon-optimized vioE gene is shown in SEQ ID NO.4.
[0012] As another limitation, the recombinant Escherichia coli overexpresses endogenous genes: trpE gene and trpD gene, deoxyarabinose heptulose phosphate synthase gene aroG gene and phosphoglycerate dehydrogenase gene serA gene;
[0013] The Gene ID of the trpE gene is 945846, the Gene ID of the trpD gene is 945109, the Gene ID of the aroG gene is 945605, and the Gene ID of the serA gene is 945258.
[0014] As a further limitation, the vioA gene, vioB gene, vioC gene and vioE gene are expressed episomally using the pCOLADuet-1 vector, and the trpE gene, trpD gene, aroG gene and serA gene are overexpressed using the pETDuet-1 vector.
[0015] As a further limitation, the expression of the vioA gene, vioB gene, vioC gene, vioE gene, aroG gene, trpE gene, trpD gene and serA gene is controlled by a strong promoter.
[0016] As a further limitation, the strong promoter includes the promoter Ptac;
[0017] The nucleotide sequence of the promoter Ptac is shown in SEQ ID NO.5.
[0018] As a further limitation, the vioA gene and the vioB gene are expressed in tandem via the RBS1 sequence, the vioC gene and the vioE gene are expressed in tandem via the RBS2 sequence, and the aroG gene and the serA gene are expressed in tandem via the RBS3 sequence;
[0019] The nucleotide sequence of RBS1 is shown in SEQ ID NO.6;
[0020] The nucleotide sequence of RBS2 is shown in SEQ ID NO.7;
[0021] The nucleotide sequence of RBS3 is shown in SEQ ID NO.8;
[0022] The nucleotide sequence of trpD and trpE expressed in tandem is shown in SEQ ID NO.9;
[0023] The nucleotide sequence of aroG and serA expressed in tandem using RBS3 is shown in SEQ ID NO.10;
[0024] The nucleotide sequence of vioA and vioB expressed in tandem using RBS1 is shown in SEQ ID NO.11;
[0025] The nucleotide sequence of vioE and vioC expressed in tandem using RBS2 is shown in SEQ ID NO.12.
[0026] As a third limitation, the Escherichia coli includes Escherichia coli BL21 (DE3).
[0027] The present invention also provides the application of the recombinant Escherichia coli, wherein the recombinant Escherichia coli produces deoxyviolacein or a product containing deoxyviolacein through fermentation.
[0028] As a limitation, the fermentation uses glycerol or glucose as a carbon source.
[0029] As another limitation, the fermentation medium is M9-YE medium.
[0030] As further defined, the M9-YE medium is composed of the following components:
[0031] 17.1 g / L disodium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate, 0.5 g / L sodium chloride, 1 g / L ammonium chloride, 1 g / L yeast extract, 1 mM magnesium sulfate, 0.1 mM calcium chloride and 10 g / L glucose.
[0032] As a third limitation, the fermentation is carried out in M9-YE medium using the recombinant Escherichia coli at 35-38°C until OD 600 After the pH value reaches 0.6-0.8, add IPTG with a final concentration of 0.05-1.0 mM, and then culture at 18-22°C for at least 48 h.
[0033] Due to the adoption of the above technical solution, the present invention has the following technical advances compared with the prior art:
[0034] The recombinant Escherichia coli constructed by the present invention overexpresses endogenous aroG gene and serA gene. In the Escherichia coli, the aroG gene encodes deoxyarabinose heptulose phosphate synthase (DS), which catalyzes the reaction of condensing phosphoenolpyruvate (PEP) and erythrose 4-phosphate (E-4-P) shunted from the central pathway of sugar metabolism to form deoxyarabinose heptulose phosphate (DAHP), which is a precursor for de novo synthesis of tryptophan; the phosphoglycerate dehydrogenase (D-3-phosphoglycerate-dehydrogenase, PGDH) encoded by the serA gene is a key enzyme for L-serine synthesis (a substrate for tryptophan synthesis).
[0035] The recombinant Escherichia coli constructed by the present invention can produce 348 mg / L of deoxypurobactin under shake flask fermentation conditions without the additional addition of tryptophan, thereby reducing the cost of preparing deoxypurobactin by fermentation and having the potential for industrial application. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] The accompanying drawings are used to provide further understanding of the present invention and constitute a part of the specification. They are used to explain the present invention together with the embodiments of the present invention and do not constitute a limitation of the present invention.
[0037] In the attached picture:
[0038] Figure 1 This is the standard curve of deoxyviolacein;
[0039] Figure 2 Agarose gel electrophoresis diagram for genome knockout validation of recombinant E. coli strains;
[0040] Figure 3 is the map of plasmid pET-tac-tac-aroG-serA;
[0041] Figure 4 is the map of plasmid pET-tac-trpE-trpD-tac-aroG-serA;
[0042] Figure 5 is the map of plasmid pCO-tac-vioA-vioB-tac-vioE-vioC;
[0043] Figure 6 The bar graph shows the production of deoxypurobactin by recombinant Escherichia coli knocking out different genes;
[0044] Figure 7 This is a color comparison chart of deoxypurpurogenin produced by recombinant Escherichia coli B3SEC in M9-YE medium (sample diluted 5 times). DETAILED DESCRIPTION
[0045] The following will provide a further detailed description with reference to the embodiments.
[0046] The plasmids, endonucleases, PCR enzymes, column-based DNA extraction kits, and DNA gel recovery kits used in the following examples were commercial products, and the specific operations were performed according to the kit instructions; routine operations such as colony PCR, nucleic acid agarose gel electrophoresis, protein SDS-PAGE gel electrophoresis, heat shock transformation, electrotransformation, preparation of competent cells, and extraction and preservation of bacterial genomes were performed according to Molecular Cloning: A Laboratory Manual (Fourth Edition); sequencing of plasmids and DNA products was completed by GeneWeichi (Suzhou).
[0047] (I) Culture medium
[0048] (1) LB liquid medium: yeast extract 5 g / L, peptone 10 g / L, sodium chloride 10 g / L;
[0049] (2) LB solid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, 15 g / L agar powder;
[0050] (3) M9-YE medium: 17.1 g / L disodium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate 4 g / L, 0.5 g / L sodium chloride, 1 g / L ammonium chloride, 1 g / L yeast extract, 1 mM magnesium sulfate, 0.1 mM calcium chloride, and 10 g / L glucose;
[0051] (4) Antibiotic concentration: ampicillin 100 mg / L (liquid culture medium), ampicillin 200 mg / L (solid culture medium), kanamycin 50 mg / L, streptomycin 50 mg / L.
[0052] (II) Shake flask fermentation production of deoxypurpurogenin
[0053] The constructed strain was inoculated into 4 mL LB liquid medium containing streptomycin or kanamycin, and cultured overnight at 37°C, 210 rpm for 12 h to obtain seed solution. 500 μL of seed solution was inoculated into 25 mL M9-YE fermentation medium, and cultured at 37°C, 210 rpm until OD 600 The pH value was 0.6-0.8, and IPTG was added at a final concentration of 0.2 mM. The induction culture was continued at 20°C and 210 rpm for 48 h.
[0054] (III) Deoxypurpurogenin detection
[0055] The entire fermentation system was mixed and sampled (1 ml was sampled from each fermentation system), centrifuged at 12000 rpm for 10 min and the precipitate was collected. The precipitate was washed twice with 100% methanol and centrifuged at 12000 rpm for 5 min. After the methanol was fully evaporated, 2 mL of DMSO was added and the precipitate was dissolved by ultrasonic disruption (when the extraction is completed, the precipitate has no color), centrifuged at 12000 rpm for 5 min and the supernatant was collected, and the absorbance at 568 nm was detected by a spectrophotometer.
[0056] Use deoxyviolacein standards to make a standard curve, e.g. Figure 1 As shown, the standard curve equation is y = 0.0339x-0.0018, R 2 =0.9999, x represents the absorbance at 568 nm, and y represents the concentration of deoxyviolacein (g / L).
[0057] The yield of deoxyviolacein in the fermentation system was calculated based on the absorbance value at 568 nm and the standard curve equation.
[0058] (IV) Plasmids and strains
[0059] Table 1 Strains involved in the examples
[0060]
[0061] Example 1 Knockout of genes in the competitive pathway for tryptophan synthesis in recombinant Escherichia coli strains
[0062] The primers for constructing recombinant E. coli with competition bypass knockout are shown in Table 2.
[0063] Table 2 Primers for constructing recombinant Escherichia coli with knockout competitive bypass
[0064]
[0065]
[0066] The CRISPR / Cpf1 gene editing system was used to knock out the trpR gene encoding the tryptophan repressor protein TrpR in Escherichia coli BL21 (DE3) to obtain the recombinant bacterium B1.
[0067] The CRISPR / Cpf1 gene editing system was used to knock out the gene trpR encoding the tryptophan repressor protein TrpR and the gene pheA encoding the chorismate dehydratase in Escherichia coli BL21 (DE3) to obtain the recombinant bacterium B2.
[0068] The CRISPR / Cpf1 gene editing system was used to knock out the gene trpR encoding the tryptophan repressor protein TrpR, the gene tnaA encoding the tryptophanase TnaA, and the gene pheA encoding the chorismate dehydratase in Escherichia coli BL21 (DE3) to obtain the recombinant bacterium B3.
[0069] The construction method of recombinant bacteria B1 is as follows:
[0070] (1) Using the Escherichia coli BL21 genome as a template, ΔtrpR-up-F / R and ΔtrpR-down-F / R primers (Table 2) were used to amplify the upstream and downstream fragments of trpR by PCR, respectively. The fragments were purified by gel recovery, and the upstream and downstream amplified fragments were connected by overlapping PCR as donor DNA fragments.
[0071] (2) Using trpR-N23-F / R as primers, PCR amplification technology was used to replace the N23 sequence on the plasmid pcrEG with the N23 sequence complementary to the specific 23 bp sequence on trpR (TCGACCTGCTTAAGAATGCCTAC), thereby obtaining the pcrEG-TrpR plasmid with targeting trpR;
[0072] The PCR product was transformed into competent E. coli JM109 using the heat shock method after removing the template DNA using DpnⅠ enzyme. It was then spread on LB plates containing spectinomycin and cultured overnight at 37°C. Single colonies were picked for expansion, and the plasmids were extracted and sequenced.
[0073] (3) The pEcCpf1 plasmid was transformed into competent E. coli BL21 (DE3), and the transformed bacterial solution was spread on an LB plate containing kanamycin and cultured overnight in a 37°C incubator to obtain BL21-pEcCpf1.
[0074] (4) Prepare BL21-pEcCpf1 into electroporation competent cells.
[0075] (5) The pcrEG-TrpR plasmid and donor DNA fragment were electroporated into the electroporation competent cells of Escherichia coli BL21-pEcCpf1, spread on LB plates containing kanamycin and spectinomycin, and cultured at 37°C for 24 h. PCR colony verification was performed. The agarose gel electrophoresis pattern was as shown in Figure 2 shown.
[0076] (6) The positive clone colonies obtained by verification were picked into a 4 mL LB liquid test tube (containing rhamnose with a final concentration of 10 mM and 4 μL Kan), and after culturing at 37°C for 12 h, the pcrEG-TrpR plasmid was removed to obtain recombinant Escherichia coli BL21 (DE3) ΔtrpR, i.e., recombinant bacteria B1.
[0077] The construction method of recombinant bacteria B2 is:
[0078] (1') Using the recombinant Escherichia coli BL21 genome as a template, ΔpheA-up-F / R and ΔpheA-down-F / R primers (Table 2) were used to amplify and connect the upstream and downstream fragments of pheA by PCR, respectively, and the fragments were purified by gel recovery to obtain the donor DNA fragments.
[0079] (2') Using pheA-N23-F / R as primers, PCR amplification technology was used to replace the N23 sequence on the plasmid pcrEG with the N23 sequence complementary to the specific 23bp sequence on the pheA gene (CAGGTACTGGAGCGTATTGAAGC), thereby obtaining the plasmid pcrEG-PheA carrying the targeted pheA gene.
[0080] (3') The correctly sequenced pcrEG-PheA plasmid and DNA fragment were electroporated into the electroporation competent cells of the recombinant bacteria B1, spread on LB plates containing kanamycin and spectinomycin, cultured at 37°C for 24 h, and verified by PCR colonies.
[0081] (4') The positive clone colonies verified in step (3') were picked into a 4 mL LB liquid test tube (containing rhamnose with a final concentration of 10 mM and 4 μL Kan), cultured at 37° C. for 12 h, and then the pcrEG-PheA plasmid was removed.
[0082] (5') The strain that was successfully verified to have removed the pcrEG-PheA plasmid was inoculated into liquid LB medium containing 5 g / L glucose, and cultured at 37°C, 200 rpm for 12 h. After that, about 10 μL of the bacterial liquid was streaked on a plate containing 5 g / L glucose and 10 g / L sucrose and cultured at 37°C for 12 h.
[0083] After removing the pEcCpf1 plasmid, the recombinant Escherichia coli in which the tryptophan repressor protein encoding gene trpR and the aromatic amino acid transporter protein encoding gene pheA were successfully knocked out was obtained and named as the recombinant bacterium B2.
[0084] The construction method of recombinant bacteria B3 is:
[0085] Based on the recombinant bacteria B2, the gene tnaA in the strain was knocked out using the same method (primers ΔtnaA-up-F / R, ΔtnaA-down-F / R, tnaA-N23-F / R) to obtain the recombinant bacteria B3.
[0086] Example 2 Construction of recombinant Escherichia coli producing deoxypurpurogenin
[0087] The primer sequences involved in the deoxypurpurogenous bacteriocin synthesis pathway are shown in Table 3.
[0088] Table 3 Deoxypurpurogenin gene amplification primer sequences
[0089]
[0090]
[0091] The primer sequences involved in the genes encoding the proteins produced by tryptophan are shown in Table 4.
[0092] Table 4 Tryptophan biosynthesis pathway amplification primer sequences
[0093]
[0094]
[0095] The specific steps for constructing the recombinant expression vector used to transform Escherichia coli are as follows:
[0096] S1. Using the genome of Escherichia coli BL21 (DE3) as a template, the aroG and serA genes were amplified using two pairs of primers, pET-2-aroG-F / aroG-g0.7-R and serA-g0.7-F / serA-pET-2-R, respectively, and connected using the RBS3 sequence (nucleotide sequence as shown in SEQ ID NO.8). The fragments were constructed between the NdeI and MfeI sites at the second position of the multiple cloning site of the expression vector pETDuet-tac-tac (linear vector amplified by primers ET-tac-2R / ET-tac-2F) to form the recombinant plasmid pET-tac-tac-aroG-serA ( Figure 3 ), named TEC.
[0097] S2. The trpE-trpD gene cluster was amplified using primers pET-trpE-F / pET-trpD-R, and the fragment was constructed between the NcoI and EcoRI sites at the first position of the multiple cloning site of the expression vector pET-tac-tac-aroG-serA (linear vector amplified by primers ET-tac-1R / ET-tac-1F), obtaining the recombinant plasmid pET-tac-trpE-trpD-tac-aroG-serA ( Figure 4 ), named SEC.
[0098] S3. Using the Chromobacterium violaceum (ATCC 12472) genome as a template, Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to synthesize plasmids pCO-tac-vioAB-tac, pCO-tac-tac-vioE and pCD-tac-vioCD.
[0099] S4. Using the synthetic plasmids pCO-tac-tac-vioE and pCD-tac-vioCD as templates, the vioE-vioC gene cluster was amplified using primers pCO-2-vioE-R / pCO-vioE-RBS-R and pCO-RBS-vioC-F / pCO-vioC-2R, and inserted between the NdeI and MfeI sites of the second position of the multiple cloning site of the pCO-tac-vioAB-tac vector. The resulting plasmid after successful sequencing was pCO-tac-vioA-vioB-tac-vioE-vioC( Figure 5 ).
[0100] S5. The plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-tac-aroG-serA or pET-tac-trpED-tac-aroG-serA prepared in S4 are co-transformed into recombinant Escherichia coli into the recombinant bacteria B1, B2, and B3 constructed in Example 1 to obtain 6 recombinant Escherichia coli strains B1TEC, B2TEC, B3TEC, B1SEC, B2SEC, and B3SEC.
[0101] Example 3 Comparison of shake flask yields of recombinant bacteria
[0102] The six recombinant E. coli strains B1TEC, B2TEC, B3TEC, B1SEC, B2SEC and B3SEC constructed in Example 2 were grown overnight on a resistance agar LB plate and then inoculated into 4 mL LB medium with the corresponding antibiotics as the initial seed solution; cultured at 37 ° C, 210 rpm for 12 h, 0.5 mL of the initial seed solution was inoculated into 25 mL medium with the corresponding antibiotics, and continued to grow at 37 ° C, 210 rpm until OD 600 =0.8, then add IPTG with a final concentration of 0.2 mM, and continue inducing culture at 20°C and 210 rpm for 48 h.
[0103] 1 mL of sample was taken from each fermentation system, and the precipitate was collected after centrifugation at 12000 rpm for 10 min. The precipitate was fully washed twice with 100% methanol, and centrifuged at 12000 rpm for 5 min. After the methanol was fully volatilized, 2 mL of DMSO was added and the precipitate was dissolved by ultrasonic disruption (when the extraction was completed, the precipitate had no color), and the supernatant was collected after centrifugation at 12000 rpm for 5 min. The obtained supernatant was measured for absorbance at 568 nm by a spectrophotometer, and the yield of deoxyviolacein in the fermentation system was calculated according to the deoxyviolacein standard curve equation. The results are shown in FIG. Figure 6 and Figure 7 shown.
[0104] Depend on Figure 6 and Figure 7 It can be seen that after fermentation, the yield of recombinant bacteria B1, B2, and B3 increases further with the increase in the number of gene knockouts. At the same time, it can be seen that with the overexpression of anthranilate synthase I gene trpE, anthranilate synthase II gene trpD, 3-deoxy-D-arabinoheptulonic acid-7-phosphate gene aroG, and 3-phosphoglyceraldehyde dehydrogenase gene serA in the host, the synthesis capacity of deoxypurpurogenin is significantly improved; among them, B3SEC (knockout of tnaA, trpR, and pheA; overexpression of trpE, trpD, aroG, and serA at the same time) shows a stronger deoxypurpurogenin synthesis capacity. The final recombinant Escherichia coli can produce 348 mg / L of deoxypurpurogenin under shake flask fermentation conditions without the addition of tryptophan, which reduces the cost of fermentation preparation of deoxypurpurogenin and has the potential for industrial application.
[0105] Although the present invention has been disclosed as above in terms of preferred embodiments, it is not intended to limit the present invention. Those skilled in the art should understand that various changes and modifications may be made without departing from the spirit and scope of the present invention, which should all be covered by the scope of the claims of the present invention.
Claims
1. A recombinant Escherichia coli producing deoxypurpurogenin, characterized in that: The method uses Escherichia coli as a starting strain, knocks out one or more of the endogenous tnaA gene, trpR gene and pheA gene, and expresses the vioA gene, vioB gene, vioC gene and vioE gene in Chromobacterium violaceum in a free manner.
2. The recombinant Escherichia coli according to claim 1, characterized in that The vioA gene, vioB gene, vioC gene and vioE gene are codon optimized; The codon-optimized vioA gene sequence is shown in SEQ ID NO.1; The codon-optimized vioB gene sequence is shown in SEQ ID NO.2; The codon-optimized vioC gene sequence is shown in SEQ ID NO.3; The codon-optimized vioE gene sequence is shown in SEQ ID NO.
4.
3. The recombinant Escherichia coli according to claim 1, characterized in that The recombinant Escherichia coli overexpresses endogenous trpE gene, trpD gene, aroG gene and serA gene.
4. The recombinant Escherichia coli according to claim 3, characterized in that The pCOLADuet-1 vector is used to episomally express the vioA gene, vioB gene, vioC gene and vioE gene, and the pETDuet-1 vector is used to overexpress the trpE gene, trpD gene, aroG gene and serA gene.
5. The recombinant Escherichia coli according to claim 3 or 4, characterized in that A strong promoter is used to control the expression of the vioA gene, vioB gene, vioC gene, vioE gene, aroG gene, trpE gene, trpD gene and serA gene.
6. The recombinant Escherichia coli according to claim 5, characterized in that The strong promoter includes the promoter Ptac.
7. The recombinant Escherichia coli according to claim 3, 4 or 6, characterized in that The vioA gene and the vioB gene are expressed in tandem through the RBS1 sequence, the vioC gene and the vioE gene are expressed in tandem through the RBS2 sequence, and the aroG gene and the serA gene are expressed in tandem through the RBS3 sequence.
8. The recombinant Escherichia coli according to claim 1, characterized in that The Escherichia coli includes Escherichia coli BL21 (DE3).
9. The use of the recombinant Escherichia coli according to any one of claims 1 to 8, characterized in that: The recombinant Escherichia coli produces deoxyviolacein by fermentation.
10. The use according to claim 9, characterized in that: The fermentation uses glycerol or glucose as a carbon source.
Citation Information
Patent Citations
Method for preparing deoxidized violacein and special recombinant bacterium
CN101319219A
Microorganisms of escherichia coli having enhanced L-tryptophan production and method for producing L-tryptophan by using same
CN104204189A
An engineering bacterium producing violacein and applications thereof
CN104694448A
Construction method and application of recombinant escherichia coli for producing indigo blue
CN118086164A
Genetic engineering strain for producing deoxyviolacein as well as construction method and application of genetic engineering strain
CN118979050A
